Perhaps the new CFO can offer some other creative

Perhaps the new CFO can offer some other creative financing alternatives to the management team as well as show them "cause and effect" details of standard financing means. i.e. R/S to raise price, lower share count, and create poor shareholder support - however, releasing revenue generating product, or new institutional investment, or PR on favorable clinical approvals could all be considered as "cause and effect" for management decision-making, and thus stimulate shareholder support.